France’s investment banking market recovered strongly in 2025 but that doesn’t mean domestic banks are happy. The market is ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

New long-term clinical data for Blueprint Medicines' drug Ayvakit (avapritinib) were presented at the ASH congress in Orlando, reinforcing the treatment's pr ...

Two treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical ...

The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at [email ...

MILWAUKEE--(BUSINESS WIRE)--Sep 15, 2025--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi .Click here to learn how to join our investigation and obtain … This ...